logo
RSM's FY2025 Global Tax conference focuses on key tax issues

RSM's FY2025 Global Tax conference focuses on key tax issues

Yahoo04-04-2025

RSM, a provider of assurance, tax and consulting services, hosted its Global Tax Conference for FY2025 in Amsterdam, Netherlands.
The event brought together tax experts from 49 countries to discuss critical international tax developments shaping the business landscape, the company said.
The conference followed a 'strong' year for RSM's global tax practice, which saw an 11% rise in annual tax revenues.
The three-day event provided a platform for RSM's global tax specialists to delve into technical areas including mergers and acquisitions, transfer pricing, and global indirect tax, through a series of specialist breakout sessions.
RSM International CEO E.J. Nedder said: 'The Global Tax Conference is a powerful opportunity for RSM to unite our global community and leverage our brand, expertise and vision. This enables us to continually strengthen our ability to deliver consistent, high-quality experiences for both our people and our clients.
'This conference is a celebration of collaboration, where innovation drives progress and enhances the value we create. 'One RSM' is more than just a theme – it reflects our commitment to shared success and our unwavering dedication to working together as one.'
Delegates at the conference also received forward-looking insights into the tax developments expected to shape the landscape in 2025, RSM said.
The three-day event, held under the theme 'One RSM,' explored the issues currently influencing global tax policy.
This covered the OECD's Pillar 2 framework, including the STTR adoption by developing countries, and the need for businesses to manage rising compliance and tax liabilities in a changing global tax environment.
Commenting on the complexities behind Pillar 2's implementation, RSM Netherlands director Juan Dosal said: 'As countries adopt varying interpretations and timelines for Pillar 2, multinational enterprises (MNEs) face significant compliance complexities, increased audit scrutiny, and the risk of double taxation.
'Some jurisdictions may delay implementation or introduce deviations from the OECD framework, creating a patchwork of rules that escalates operational costs and complicates tax planning.
'To navigate this, MNEs are centralising their Pillar 2 compliance strategies, leveraging advanced technology for real-time reporting, and proactively engaging with tax authorities to resolve ambiguities.
'While divergence in national policies raises concerns about short-term tax competition, there is growing evidence of a shift toward long-term global alignment.
"Initiatives like the EU's Directive on Administrative Cooperation (DAC9)—which introduces standardised reporting and central filing for MNEs by December 2025—are enhancing data-sharing and reducing administrative burdens.'
"RSM's FY2025 Global Tax conference focuses on key tax issues" was originally created and published by The Accountant, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UK trade secretary to seek exemption from US steel and aluminium tariffs
UK trade secretary to seek exemption from US steel and aluminium tariffs

Yahoo

timea day ago

  • Yahoo

UK trade secretary to seek exemption from US steel and aluminium tariffs

The UK's trade secretary, Jonathan Reynolds, will meet his US counterpart next week to thrash out a timeline for exempting the UK from US steel and aluminium tariffs after Donald Trump announced he would double them. British officials are seeking clarity on the implications of Trump's announcement on Friday night that he planned to double the tariffs from 25% to 50% from Wedneday 4 June, piling further pressure on global steel trade. Reynolds is expected to meet his US counterpart, Jamieson Greer , at the OECD meeting in Paris next week. He will seek to agree a timeline for implementing the deal agreed to lower steel, aluminium, auto and other product tariffs. A UK government spokesperson said: 'The UK was the first country to secure a trade deal with the US earlier this month and we remain committed to protecting British business and jobs across key sectors, including steel.' 'We are engaging with the US on the implications of the latest tariff announcement and to provide clarity for industry.' The Guardian reported that British officials were intensifying trade talks with the US and hope to see the deal implemented within weeks. A government source said: 'Some countries are viewing the court ruling as an indication that they were right not to negotiate over tariffs. We're taking the opposite view, and trying to get this deal implemented as soon as possible.' Trump and Keir Starmer announced a US-UK trade deal earlier this month under which on British steel and aluminium will be reduced to zero, and tariffs on up to 100,000 British cars a year will be reduced from 25% to 10%. The deal did not cover Trump's blanket 10% tariffs on all foreign imports, which a federal court overturned last week, arguing that the US president had overstepped his powers. An appeals court paused the ruling and said Trump's tariffs could continue while it examines the arguments. The European Commission said on Saturday that it 'strongly' regretted Trump's decision to double steel and aluminium tariffs, and warned that the EU was prepared to retaliate. 'This decision adds further uncertainty to the global economy and increases costs for consumers and businesses on both sides of the Atlantic,' a spokesperson for the commission said, adding that 'the tariff increase also undermines ongoing efforts to reach a negotiated solution'. 'The EU is prepared to impose countermeasures, including in response to the latest U.S. tariff increase.' 'The European Commission is currently finalising consultations on expanded countermeasures. If no mutually acceptable solution is reached, both existing and additional EU measures will automatically take effect on 14 July – or earlier, if circumstances require.'

3 Top Canadian Stocks With Healthy Growth Prospects
3 Top Canadian Stocks With Healthy Growth Prospects

Yahoo

time2 days ago

  • Yahoo

3 Top Canadian Stocks With Healthy Growth Prospects

Written by Rajiv Nanjapla at The Motley Fool Canada The S&P/TSX Composite Index has rebounded strongly from its April lows, rising 18.2%. Easing trade tensions and favourable commentary from the Organization for Economic Co-operation and Development (OECD) on the Canadian economy have improved investors' sentiments, driving the equity markets higher. Amid rising investor confidence, I am bullish on the following three stocks, which offer healthier growth prospects. Dollarama (TSX:DOL) is a discount retailer operating 1,616 stores across Canada, with 85% of Canadians having at least one store within a 10-kilometre vicinity. The company's superior direct-sourcing model, purchasing capabilities, and efficient logistics system have helped reduce its expenses, enabling it to offer a wide array of products to its customers at competitive prices. Therefore, the Montreal-based retailer enjoys healthy same-store sales even in challenging environments. Supported by its healthy and reliable financials, the company has delivered returns of approximately 4,580% over the last 15 years, at an annualized rate of 29.2%. Moreover, Dollarama expects to increase its store network to 2,200 by the end of fiscal 2034. Considering its capital-efficient model, quick sales ramp-up, and lower store network maintenance capex requirements, these expansions could boost both its top and bottom lines. The retailer also has solid exposure to the Latin American market, with a 60.1% stake in Dollarcity, which operates 632 discount stores across the region. Meanwhile, Dollarcity continues to expand its store network, aiming to reach 1,050 by the end of fiscal 2032. Dollarama can also increase its stake to 70% by exercising its option by 2027. Furthermore, Dollarama is venturing into the Australian retail market through the acquisition of the Reject Shop. The company is working on acquiring the Australian discount retailer for $233 million and expects to complete the deal in the second half of this year. Considering these growth prospects, I am bullish on Dollarama. Second on my list would be Shopify (TSX:SHOP), which had reported a healthy first-quarter performance earlier this month. Its GMV (gross merchandise value) grew 23% to $74.8 billion, driven by the expansion of its customer base and same-store sales growth among existing merchants. Also, its topline grew 26.8% amid strong performance from subscription and merchant solutions. Despite the topline growth, the company incurred a net loss of $682 million, mainly due to a $900 million decline in its equity investments. Removing these one-time expenses, its adjusted EPS (earnings per share) stood at $0.25, a 25% increase from the previous year's quarter. Meanwhile, more small and medium-sized businesses are adopting an omnichannel selling model, thereby driving demand for Shopify's products and services. The company is developing innovative and artificial intelligence (AI)-powered products, venturing into new markets, and growing the penetration of its Shopify Payments, which could support its topline growth. The company is also utilizing AI to enhance its operational capabilities and improve operational efficiency. Considering all these factors, I believe the uptrend in Shopify's financials will continue, which will support its stock price growth. My final pick would be Celestica (TSX:CLS), which has witnessed solid buying over the last weeks, rising 98% from its previous month's lows. The company's impressive first-quarter performance and improving investors' sentiments have driven its stock price. In the recently reported first-quarter earnings, its revenue and adjusted EPS grew 20% and 44.6%, respectively. Meanwhile, the growing use of AI has increased AI-related investments, thereby driving demand for Celstica's storage and networking products. Additionally, the company is focusing on product innovation to launch new products that meet the growing needs of its customers and strengthen its market position. Despite the recent increase in its stock price, the Toronto-based company still trades at a reasonable NTM (next 12 months) price-to-sales multiple of 1.2, making it an excellent buy. The post 3 Top Canadian Stocks With Healthy Growth Prospects appeared first on The Motley Fool Canada. Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $50 a share. Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune. Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now. Claim your FREE 5-stock report now! More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool has a disclosure policy. 2025

Turkey Pharmaceuticals Market Competition, Forecast & Opportunities, 2030: High-Value Segments and Digital Transformation Drive Growth
Turkey Pharmaceuticals Market Competition, Forecast & Opportunities, 2030: High-Value Segments and Digital Transformation Drive Growth

Yahoo

time4 days ago

  • Yahoo

Turkey Pharmaceuticals Market Competition, Forecast & Opportunities, 2030: High-Value Segments and Digital Transformation Drive Growth

The Turkey Pharmaceuticals Market offers opportunities in expanding generic drug capabilities and digital healthcare innovations like e-pharmacies. An aging population is driving demand, while regulatory challenges present constraints. Multinational involvement in high-value segments enhances growth potential. Turkish Pharmaceuticals Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Turkey Pharmaceuticals Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Turkey Pharmaceuticals Market was valued at USD 2.10 Billion in 2024, and is expected to reach USD 2.70 Billion by 2030, rising at a CAGR of 4.25% The market has shown steady growth driven by rising healthcare expenditure, demographic shifts, and evolving health policy frameworks. As one of the leading pharmaceutical markets in the MENA region, Turkey plays a key role in the global pharmaceutical landscape. The presence of multinational corporations in specialized areas such as oncology, immunology, and rare diseases has strengthened the high-value segment. Concurrently, domestic manufacturers have expanded their capabilities in generic drugs, biosimilars, and API production, increasing competitiveness and improving market access. While this enhances local capacity and self-sufficiency, it also presents challenges related to pricing and regulatory complexities. Key Market Drivers: Growing Healthcare Needs and Aging Population: The rising healthcare demands coupled with Turkey's aging population are central to the market's expansion. Healthcare spending accounts for around 4.5% of the country's GDP, with per capita expenditure increasing significantly since the implementation of the Healthcare Transformation Program in 2002. According to OECD data, spending per capita has reached USD 857, reflecting a continued investment in improving healthcare access and quality. An aging population is leading to a growing prevalence of non-communicable diseases such as cancer, diabetes, cardiovascular conditions, arthritis, and Alzheimer's. This epidemiological transition is increasing the need for long-term treatments and pharmaceuticals, significantly influencing drug consumption trends and creating long-term opportunities for the industry. Key Market Challenges: Pricing and Reimbursement Constraints A major constraint in the Turkish pharmaceutical market is the government's strict pricing and reimbursement mechanisms aimed at cost containment. The use of an international reference pricing system: based on the lowest drug prices in selected European countries: often results in suppressed pricing levels. Additionally, the long-standing artificial exchange rate applied to pharmaceutical imports further reduces the profitability of international companies operating in Turkey. These pricing models, coupled with prolonged reimbursement approval timelines, limit the financial viability of launching new and innovative drugs. Such policies have the potential to deter foreign investment, limit product variety, and reduce patient access to cutting-edge therapies, ultimately affecting market innovation and growth. Key Market Trends: Digitalization of Healthcare and E-Pharmacy Expansion The Turkish pharmaceutical industry is increasingly embracing digital transformation through the adoption of telemedicine, electronic prescriptions, health informatics, and online pharmacies. These developments are streamlining healthcare delivery, improving compliance, and opening up new revenue opportunities. The integration of e-prescription systems has enhanced drug traceability and inventory oversight for pharmacies. With the rising popularity of online purchasing: especially among urban consumers: pharmaceutical firms are expanding their e-commerce capabilities. Additionally, the normalization of digital consultations and remote healthcare services post-pandemic has led to an uptick in outpatient pharmaceutical sales, signaling a fundamental shift in how medicines are accessed and consumed. Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.1 Billion Forecasted Market Value (USD) by 2030 $2.7 Billion Compound Annual Growth Rate 4.2% Regions Covered Turkey Report ScopeKey Market Players: Amgen Inc. Bilim Ilac Sanayii ve Ticaret Anonim Sirketi Bristol-Myers Squibb Company EastPharma Ltd Ferring Ilac Sanayi ve Ticaret Ltd Sti (Ferring Global) Gensenta Ilac Sanayi ve Ticaret A.S. GlaxoSmithKline Turkey ITALFARMACO S.p.A. Menarini Turkiye (Menarini Group) Merck & Co. MS Pharma Novartis Turkey Pfizer Turkey Takeda Pharmaceutical Company Turkey Pharmaceuticals Market, By Drug Type: Generic Branded Drugs Turkey Pharmaceuticals Market, By Product Type: Over-The-Counter Drugs Prescription Drugs Turkey Pharmaceuticals Market, By Application: Cardiovascular Oncology Metabolic Disorder Musculoskeletal Anti-infective Others Turkey Pharmaceuticals Market, By Distribution Channel: Retail Pharmacy Hospital Pharmacy E-Pharmacy Turkey Pharmaceuticals Market, By Region: Marmara Region Central Anatolia Eastern Anatolia Region South-Eastern Anatolia Region Aegean Region Mediterranean Region Black Sea Region For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Turkish Pharmaceuticals Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store